Global University Venturing

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

CAS-backed AI processor provider Cambricon, valued at $2.5bn in 2018, floated on Shanghai's Star Market.

Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

The fund will target early-stage digital health applications, medical devices and therapeutics developed on the Anschutz Medical Campus.

Columbia University’s Vor Biopharma has collected more capital from shareholders including Osage University Partners, Johnson & Johnson and PureTech Health.

UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

UCSF has unveiled Nine Square Therapeutics with $50m in series A capital from founding investor Apple Tree Partners.

University of Oxford emeritus professor Gordon Clark will oversee IP Group's approach to ethical dealmaking and report to the firm's board of directors.

The ultrasound therapeutics developer, a University of Oxford spinout, has raised series B2 funding in the run-up to clinical testing of its cancer drug delivery platform.